Delivery Order SPE2DB24D1205-SPE2DB24FCTBF

Award Date 7/24/24
Potential Completion Date 7/25/24
Potential Value $2.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Mesalamine ER 0.375 gram capsules. The contract has a ceiling value of $4,478.29 and a completion date of July 14, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global...
This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical for the supply of MESALAMINE ER 0.375 GRAM CAP 120S. The $3,031.10 firm-fixed-price contract has a completion date of July 24, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a wide range...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,698.11, is for the delivery of MESALAMINE ER 0.375 GRAM CAP 120S, a pharmaceutical product. The contract is a firm fixed-price delivery order, with an ultimate completion date of April 23, 2025. This award is associated with a larger Indefinite Delivery Contract (IDC) held by...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,568,093,215 units of Mesalamine DR 400 mg capsules. The contract has a ceiling value of $4,230.04 and a performance period through May 1, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with DLA Troop Support Medical, valued at $999,999,999.00, which provides a...
This is a Firm Fixed Price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Mesalamine Extended-Release 0.375 gram capsules in packages of 120. The contract has a ceiling value of $1,362.68 and a period of performance through May 13, 2025. There is no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Mesalamine DR 400 mg capsules (180s). The contract has a ceiling value of $2,632.04 and a completion date of June 13, 2025. The award is not set aside and was made on June 12, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00,...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of MESALAMINE ER 0.375 GRAM CAP 120S, a pharmaceutical product, with a ceiling value of $2,654.36. The contract is a firm fixed price, delivery order type with a period of performance extending to July 9, 2025. This contract is not set aside and was awarded on an open...
This is a delivery order awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) for the supply of pharmaceutical products, including Mesalamine DR 400 mg capsules. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $4,272.71 and a completion date of July 15, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of the medication Mesalamine DR 400 mg Capsule (180s). The contract has a ceiling value of $2,666.26 and an ultimate completion date of May 23, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Mesalamine DR 400 mg capsules, a medication used to treat certain gastrointestinal conditions. The contract has a ceiling value of $11,025.57 and is a firm fixed-price delivery order, with an ultimate completion date of June 27, 2025. The contract is not designated as a...
  • SPE2DB24D1205
    Indefinite Delivery Contract
  • SPE2DB24D1205-SPE2DB24FCTBF
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Mesalamine ER 0.375 gram capsules. The contract has a ceiling value of $2,906.07 and is a firm-fixed price contract with an ultimate completion date of July 25, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which allows the agency to efficiently procure a wide range of pharmaceutical and medical supplies to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation.

Generated 10/23/24, 9:27 AM